Elevated levels of asymmetric dimethylarginine in chronic heart failure: A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol

S. Von Haehling, S. M. Bode-Böger, J. Martens-Lobenhoffer, M. Rauchhaus, J. C. Schefold, S. Genth-Zotz, T. Karhausen, M. Cicoira, S. D. Anker, W. Doehner

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level was studied in relation to peripheral blood flow and vasodilator capacity. Further, the effects of allopurinol on concentrations of reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were tested in a double-blind design. ADMA level was found to be elevated in CHF patients as compared with controls and increased in parallel with New York Heart Association (NYHA) class and exercise capacity (all P 0.0001). The level of ADMA predicted resting blood flow (P 0.05) and postischemic vasodilator capacity (P 0.001). Sixty eight patients died during the follow-up period. The level of ADMA predicted survival after multivariable adjustment (P = 0.04). Allopurinol reduced uric acid (UA) concentration (P 0.001) and decreased ROS concentration (allantoin, P 0.01). Allopurinol lowered ADMA concentration (P = 0.02); postischemic vasodilation as well as endothelium-dependent vasodilation (both P 0.05) improved. ADMA may be a pathophysiologic factor that is modulated by ROS accumulation and contributes to impaired vascular regulation in CHF.

Original languageEnglish
Pages (from-to)506-512
Number of pages7
JournalClinical Pharmacology and Therapeutics
Volume88
Issue number4
DOIs
Publication statusPublished - Oct 2010

Fingerprint

Allopurinol
Therapeutic Uses
Vasodilator Agents
Reactive Oxygen Species
Heart Failure
Vasodilation
Allantoin
N,N-dimethylarginine
Uric Acid
Endothelium
Blood Vessels
Nitric Oxide
Exercise
Survival

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

Elevated levels of asymmetric dimethylarginine in chronic heart failure : A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. / Von Haehling, S.; Bode-Böger, S. M.; Martens-Lobenhoffer, J.; Rauchhaus, M.; Schefold, J. C.; Genth-Zotz, S.; Karhausen, T.; Cicoira, M.; Anker, S. D.; Doehner, W.

In: Clinical Pharmacology and Therapeutics, Vol. 88, No. 4, 10.2010, p. 506-512.

Research output: Contribution to journalArticle

Von Haehling, S, Bode-Böger, SM, Martens-Lobenhoffer, J, Rauchhaus, M, Schefold, JC, Genth-Zotz, S, Karhausen, T, Cicoira, M, Anker, SD & Doehner, W 2010, 'Elevated levels of asymmetric dimethylarginine in chronic heart failure: A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol', Clinical Pharmacology and Therapeutics, vol. 88, no. 4, pp. 506-512. https://doi.org/10.1038/clpt.2010.116
Von Haehling, S. ; Bode-Böger, S. M. ; Martens-Lobenhoffer, J. ; Rauchhaus, M. ; Schefold, J. C. ; Genth-Zotz, S. ; Karhausen, T. ; Cicoira, M. ; Anker, S. D. ; Doehner, W. / Elevated levels of asymmetric dimethylarginine in chronic heart failure : A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol. In: Clinical Pharmacology and Therapeutics. 2010 ; Vol. 88, No. 4. pp. 506-512.
@article{618560c205ee427e9d5c7fafa45e020d,
title = "Elevated levels of asymmetric dimethylarginine in chronic heart failure: A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol",
abstract = "Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level was studied in relation to peripheral blood flow and vasodilator capacity. Further, the effects of allopurinol on concentrations of reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were tested in a double-blind design. ADMA level was found to be elevated in CHF patients as compared with controls and increased in parallel with New York Heart Association (NYHA) class and exercise capacity (all P 0.0001). The level of ADMA predicted resting blood flow (P 0.05) and postischemic vasodilator capacity (P 0.001). Sixty eight patients died during the follow-up period. The level of ADMA predicted survival after multivariable adjustment (P = 0.04). Allopurinol reduced uric acid (UA) concentration (P 0.001) and decreased ROS concentration (allantoin, P 0.01). Allopurinol lowered ADMA concentration (P = 0.02); postischemic vasodilation as well as endothelium-dependent vasodilation (both P 0.05) improved. ADMA may be a pathophysiologic factor that is modulated by ROS accumulation and contributes to impaired vascular regulation in CHF.",
author = "{Von Haehling}, S. and Bode-B{\"o}ger, {S. M.} and J. Martens-Lobenhoffer and M. Rauchhaus and Schefold, {J. C.} and S. Genth-Zotz and T. Karhausen and M. Cicoira and Anker, {S. D.} and W. Doehner",
year = "2010",
month = "10",
doi = "10.1038/clpt.2010.116",
language = "English",
volume = "88",
pages = "506--512",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Elevated levels of asymmetric dimethylarginine in chronic heart failure

T2 - A Pathophysiologic link between oxygen radical load and impaired vasodilator capacity and the therapeutic effect of allopurinol

AU - Von Haehling, S.

AU - Bode-Böger, S. M.

AU - Martens-Lobenhoffer, J.

AU - Rauchhaus, M.

AU - Schefold, J. C.

AU - Genth-Zotz, S.

AU - Karhausen, T.

AU - Cicoira, M.

AU - Anker, S. D.

AU - Doehner, W.

PY - 2010/10

Y1 - 2010/10

N2 - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level was studied in relation to peripheral blood flow and vasodilator capacity. Further, the effects of allopurinol on concentrations of reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were tested in a double-blind design. ADMA level was found to be elevated in CHF patients as compared with controls and increased in parallel with New York Heart Association (NYHA) class and exercise capacity (all P 0.0001). The level of ADMA predicted resting blood flow (P 0.05) and postischemic vasodilator capacity (P 0.001). Sixty eight patients died during the follow-up period. The level of ADMA predicted survival after multivariable adjustment (P = 0.04). Allopurinol reduced uric acid (UA) concentration (P 0.001) and decreased ROS concentration (allantoin, P 0.01). Allopurinol lowered ADMA concentration (P = 0.02); postischemic vasodilation as well as endothelium-dependent vasodilation (both P 0.05) improved. ADMA may be a pathophysiologic factor that is modulated by ROS accumulation and contributes to impaired vascular regulation in CHF.

AB - Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide-dependent vasodilation. In 113 patients with chronic heart failure (CHF) and 26 controls, ADMA level was studied in relation to peripheral blood flow and vasodilator capacity. Further, the effects of allopurinol on concentrations of reactive oxygen species (ROS) and ADMA and peripheral vasodilator capacity were tested in a double-blind design. ADMA level was found to be elevated in CHF patients as compared with controls and increased in parallel with New York Heart Association (NYHA) class and exercise capacity (all P 0.0001). The level of ADMA predicted resting blood flow (P 0.05) and postischemic vasodilator capacity (P 0.001). Sixty eight patients died during the follow-up period. The level of ADMA predicted survival after multivariable adjustment (P = 0.04). Allopurinol reduced uric acid (UA) concentration (P 0.001) and decreased ROS concentration (allantoin, P 0.01). Allopurinol lowered ADMA concentration (P = 0.02); postischemic vasodilation as well as endothelium-dependent vasodilation (both P 0.05) improved. ADMA may be a pathophysiologic factor that is modulated by ROS accumulation and contributes to impaired vascular regulation in CHF.

UR - http://www.scopus.com/inward/record.url?scp=77957021340&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957021340&partnerID=8YFLogxK

U2 - 10.1038/clpt.2010.116

DO - 10.1038/clpt.2010.116

M3 - Article

C2 - 20827268

AN - SCOPUS:77957021340

VL - 88

SP - 506

EP - 512

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 4

ER -